Thermo Fisher adds Affinity to protein research offering
This article was originally published in Clinica
Laboratory equipment manufacturer Thermo Fisher Scientific has purchased antibody provider Affinity BioReagents in a move that increases its antibody offering and complements its protein research capabilities. Waltham, Massachusetts-based Thermo Fisher paid an undisclosed amount to secure Affinity, which will be integrated into the firm’s analytical technologies business. According to Thermo Fisher CEO Marijn Dekkers, this acquisition will allow the company to create end-to-end solutions for protein research applications such as Western blotting, ELISA, immunohistochemistry, flow cytometry and mass spectroscopy. Affinity (Golden, Colorado) recorded revenues of $6m for fiscal 2007 and claims to own more than 35,000 reagents.